MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Mar 11, 04:59 PM (EDT)
Price
$36.94
Change
-$2.21 (-5.64%)
Capitalization
10.96B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more

Industry: #Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EXEL with price predictions
Mar 04, 2025

EXEL in upward trend: price rose above 50-day moving average on February 19, 2025

EXEL moved above its 50-day moving average on February 19, 2025 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 13, 2025. You may want to consider a long position or call options on EXEL as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on February 13, 2025. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for EXEL crossed bullishly above the 50-day moving average on February 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 298 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EXEL broke above its upper Bollinger Band on February 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.883) is normal, around the industry mean (11.742). P/E Ratio (22.247) is within average values for comparable stocks, (66.249). Projected Growth (PEG Ratio) (2.598) is also within normal values, averaging (1.790). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (5.348) is also within normal values, averaging (229.516).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 31.73% to 37 cents per share on May 13

Exelixis EXEL Stock Earnings Reports
Q1'25
Est.
$0.38
Q4'24
Beat
by $0.16
Q3'24
Beat
by $0.13
Q2'24
Beat
by $0.53
Q1'24
Missed
by $0.06
The last earnings report on February 11 showed earnings per share of 55 cents, beating the estimate of 38 cents. With 1.44M shares outstanding, the current market capitalization sits at 10.96B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X78532.000000-2069.039000
-2.57%
Bitcoin cryptocurrency
SPY560.58-15.34
-2.66%
SPDR® S&P 500® ETF Trust
AAPL227.48-11.59
-4.85%
Apple
GME22.42-1.58
-6.58%
GameStop Corp
TSLA222.15-40.52
-15.43%
Tesla

EXEL and Stocks

Correlation & Price change

A.I.dvisor tells us that EXEL and RIGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and RIGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.49%
RIGL - EXEL
29%
Poorly correlated
-4.82%
RVMD - EXEL
28%
Poorly correlated
-6.10%
ALGS - EXEL
27%
Poorly correlated
-19.55%
RARE - EXEL
27%
Poorly correlated
-2.90%
PLX - EXEL
27%
Poorly correlated
-0.43%
More